TY - JOUR
T1 - Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols
AU - Tomizawa, Daisuke
AU - Watanabe, Tomoyuki
AU - Hanada, Ryoji
AU - Horibe, Keizo
AU - Horikoshi, Yasuo
AU - Iwamoto, Shotaro
AU - Kinoshita, Akitoshi
AU - Moritake, Hiroshi
AU - Nakayama, Hideki
AU - Shimada, Akira
AU - Taga, Takashi
AU - Takahashi, Hiroyuki
AU - Tawa, Akio
AU - Terui, Kiminori
AU - Hori, Hiroki
AU - Kawano, Yoshifumi
AU - Kikuta, Atsushi
AU - Manabe, Atsushi
AU - Adachi, Souichi
N1 - Funding Information:
The authors thank all the investigators, coworkers, and members of participating hospitals in the AML studies conducted by the CCLSG, TCCSG, JACLS, KYCCSG, and JPLSG. The authors also thank Dr. Julian Tang of the Department of Education for Clinical Research, National Center for Child Health and Development, for critical comments and editorial assistance. This work was supported by a Grant for Innovative Cancer Medicine Research from the Ministry of Health, Labour, and Welfare of Japan (H26-KakushintekiGan-Ippan-061).
Publisher Copyright:
© 2015, The Japanese Society of Hematology.
PY - 2015/9/13
Y1 - 2015/9/13
N2 - As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age ≥15 years at diagnosis), 164 as infants (0–1 year), 413 as younger children (2–11 years), and 161 as older children (12–14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 %) was significantly lower than that of the other three groups (P = 0.019): 68.7 % for infants, 73.2 % for younger children, and 75.5 % for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 %) than that in infants (14.8 %), younger children (10.2 %), and older children (13.8 %). Multivariate analysis showed age ≥15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.
AB - As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age ≥15 years at diagnosis), 164 as infants (0–1 year), 413 as younger children (2–11 years), and 161 as older children (12–14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 %) was significantly lower than that of the other three groups (P = 0.019): 68.7 % for infants, 73.2 % for younger children, and 75.5 % for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 %) than that in infants (14.8 %), younger children (10.2 %), and older children (13.8 %). Multivariate analysis showed age ≥15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.
KW - Acute myeloid leukemia
KW - Adolescents
KW - Children
UR - http://www.scopus.com/inward/record.url?scp=84941259016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941259016&partnerID=8YFLogxK
U2 - 10.1007/s12185-015-1825-x
DO - 10.1007/s12185-015-1825-x
M3 - Article
C2 - 26126642
AN - SCOPUS:84941259016
VL - 102
SP - 318
EP - 326
JO - International Journal of Hematology
JF - International Journal of Hematology
SN - 0925-5710
IS - 3
ER -